Moss, 24 April 2020
Gentian Diagnostics AS announces its results for the first quarter of 2020. The highlights include:
• Record sales revenues of MNOK 16.2 in 1Q20, up from MNOK 10.6 in 1Q19
• Sales growth of 53 % is based on strong performance of all product lines. Sales grew by 42 % YoY on a currency neutral basis
• New publications of clinical study results confirm GCAL as a promising biomarker for earlier detection and better prediction of severity of an infection
Please find the report and results presentation enclosed. The documents will also be made available on www.gentian.no.
For further information, please contact:
Hilja Ibert
CEO, Gentian Diagnostics
E-mail: hilja.ibert@gentian.no
Cell Phone: +47 919 05 242
Njaal Kind
CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone. +47 919 06 525